Stuttgart - Delayed Quote EUR

Seres Therapeutics Inc (1S9.SG)

Compare
0.8408
+0.0048
+(0.57%)
At close: January 24 at 5:43:39 PM GMT+1
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
126,325.0000
126,325.0000
7,128.0000
144,927.0000
33,215.0000
Operating Expense
168,715.0000
234,308.0000
253,618.0000
209,420.0000
121,345.0000
Operating Income
-42,390.0000
-107,983.0000
-246,490.0000
-64,493.0000
-88,130.0000
Net Non Operating Interest Income Expense
-5,207.0000
-5,875.0000
-2,962.0000
-40.0000
-1,978.0000
Other Income Expense
-20,848.0000
134.0000
-705.0000
-1,045.0000
981.0000
Pretax Income
-68,445.0000
-113,724.0000
-250,157.0000
-65,578.0000
-89,127.0000
Net Income Common Stockholders
-25,475.0000
-113,724.0000
-250,157.0000
-65,578.0000
-89,127.0000
Diluted NI Available to Com Stockholders
-25,475.0000
-113,724.0000
-250,157.0000
-65,578.0000
-89,127.0000
Basic EPS
-0.21
-0.89
-2.31
-0.72
-1.12
Diluted EPS
-0.21
-0.89
-2.31
-0.72
-1.12
Basic Average Shares
145,103.1550
128,003.2940
108,077.0430
91,702.8660
79,789.2200
Diluted Average Shares
145,103.1550
128,003.2940
108,077.0430
91,702.8660
79,789.2200
Total Operating Income as Reported
-42,390.0000
-107,983.0000
-246,490.0000
-64,493.0000
-88,130.0000
Total Expenses
168,715.0000
234,308.0000
253,618.0000
209,420.0000
121,345.0000
Net Income from Continuing & Discontinued Operation
-25,475.0000
-113,724.0000
-250,157.0000
-65,578.0000
-89,127.0000
Normalized Income
-68,445.0000
-113,724.0000
-250,157.0000
-65,578.0000
-89,127.0000
Interest Income
5,501.0000
7,301.0000
3,058.0000
2,870.0000
946.0000
Interest Expense
10,708.0000
13,176.0000
6,020.0000
2,910.0000
2,924.0000
Net Interest Income
-5,207.0000
-5,875.0000
-2,962.0000
-40.0000
-1,978.0000
EBIT
-57,737.0000
-100,548.0000
-244,137.0000
-62,668.0000
-86,203.0000
EBITDA
-51,722.0000
-94,305.0000
-237,508.0000
-56,721.0000
-79,625.0000
Reconciled Depreciation
6,015.0000
6,243.0000
6,629.0000
5,947.0000
6,578.0000
Net Income from Continuing Operation Net Minority Interest
-68,445.0000
-113,724.0000
-250,157.0000
-65,578.0000
-89,127.0000
Normalized EBITDA
-51,722.0000
-94,305.0000
-237,508.0000
-56,721.0000
-79,625.0000
12/31/2020 - 8/28/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade